OPERA-02
Phase 3 Recruiting
1,000 enrolled
DEBRA
Phase 3 Recruiting
1,670 enrolled
Adjuvant WIDER
Phase 3 Recruiting
1,400 enrolled
EvoPAR-BR01
Phase 3 Recruiting
500 enrolled
CAMBRIA-1
Phase 3 Recruiting
4,300 enrolled
INAVO123
Phase 3 Recruiting
450 enrolled
RAMP 301
Phase 3 Recruiting
270 enrolled
ELEGANT
Phase 3 Recruiting
4,220 enrolled
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Phase 3 Recruiting
4,800 enrolled
OPERA-01
Phase 3 Recruiting
510 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
POWER II
Phase 3 Recruiting
354 enrolled
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Phase 3 Recruiting
240 enrolled
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Phase 3 Recruiting
1,903 enrolled
MATAO
Phase 3 Recruiting
540 enrolled
TREAT ctDNA
Phase 3 Recruiting
220 enrolled
CAMBRIA-2
Phase 3 Recruiting
5,500 enrolled
TALES
Phase 3 Recruiting
309 enrolled
LEPRE
Phase 3 Recruiting
132 enrolled
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3 Recruiting
766 enrolled
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Phase 3 Recruiting
350 enrolled
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Phase 3 Recruiting
1,946 enrolled